Skip to main content
. 2016 Feb 17;6:21610. doi: 10.1038/srep21610

Table 1. Baseline patient characteristics and treatment regimens.

  Total (N = 345) Discharged alive (N = 272) Died in-hospital (N = 73) p value
Age (years) 72 (54–82) 67 (49–79) 83 (75.5–86) <0.001
Sex (female) 134 (38.8%) 101 (37.1%) 33 (45.2%) 0.225
Cavity on X-ray 144 (41.7%) 116 (42.6%) 28 (38.4%) 0.593
Bilateral infiltration on X-ray 253 (73.3%) 189 (69.5%) 64 (87.7%) 0.002
Previous history of TB treatment 38 (11.0%) 29 (10.7%) 9 (12.3%) 0.676
Extra-pulmonary pulmonary TB 33 (9.6%) 27 (9.9%) 6 (8.2%) 0.824
Diabetes 88 (25.5%) 69 (25.4%) 19 (26.0%) 0.881
Immunosuppression 42 (12.2%) 27 (9.9%) 15 (20.5%) 0.025
Chronic cardiac disease 49 (14.2%) 30 (11.0%) 19 (26.0%) 0.002
Chronic pulmonary disease 41 (11.9%) 29 (10.7%) 12 (16.4%) 0.220
Chronic liver disease 40 (11.6%) 23 (8.5%) 17 (23.3%) 0.002
Chronic renal disease 42 (12.2%) 28 (10.3%) 14 (19.2%) 0.045
Active malignancy 41 (11.9%) 26 (9.6%) 15 (20.5%) <0.001
Hemoglobin (g/dL) 11 (9.6–12.7) 11.4 (10.0–13.1) 9.9 (8.6–11.2) <0.001
Aspartate aminotransferase (IU/dL) 26 (19–44) 24 (18–38) 39 (25–76.5) <0.001
Alanine aminotransferase (IU/dL) 18 (12–32) 17.5 (12–30.75) 21 (14–41.5) 0.082
Blood urea nitrogen (mg/dL) 15 (12.0–23.0) 14 (11.0–19.8) 23 (16.5–33.0) <0.001
Creatinine (mg/dL) 0.65 (0.51–0.90) 0.65 (0.53–0.88) 0.67 (0.48–1.12) 0.501
Treatment regimen       <0.001
HRZE 200 (58.0%) 182 (66.9%) 18 (24.7%)  
HRE 114 (33.0%) 74 (27.2%) 40 (54.8%)  
The other regimens 31 (9.0%) 16 (5.9%) 15 (20.5%)  

Continuous variables were presented as median (interquartile range).

%: proportion to numbers of total patients (N = 345), patients discharged alive (N = 272), or patients died in-hospital (N = 73).

HRZE: isoniazid + rifampicin + pyrazinamide + ethambutol. HRE: isoniazid + rifampicin + ethambutol.

p value: Fisher’s exact test or Mann-Whitney rank sum test was used for binary variables and ontinuous variables, respectively. Treatment regimens were compared using chi-square test.